Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $415M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Kamada-AAT for Inhalation, 80mg | Phase 2 | Alpha-1 Antitrypsin Deficiency |
| Alpha 1-Antitrypsin | Phase 3 | Alpha 1-Antitrypsin Deficiency |
| KamRAB - HRIG | Phase 3 | Rabies |
| GLASSIA® and Institution standard of care (SOC) | Phase 2 | Transplantation, Lung Rejection |
| Alpha-1 Antitrypsin | Phase 2 | New Onset Type-1 Diabetes |
| Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | Phase 2 | Cystic Fibrosis |
| Active rabies vaccine (US-FDA approved) | Phase 3 | Rabies |
| Kamada Anti-SARS-CoV-2 | Phase 2 | Covid19 |
| Alpha-1 Antitrypsin 40mg (AAT, Glassia®) | Phase 2 | Type 1 Diabetes Mellitus |
| Kamada AAT for inhalation | Phase 3 | Emphysema |
| Kamada-API | Phase 3 | Alpha 1-Antitrypsin Deficiency |
Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.